PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1447642
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1447642
Ophthalmology Drugs Market - By Therapeutic Class (Anti-VEGF, Anti-glaucoma), Indication (Dry Eye, Allergy), Route of Administration (Topical), Type (Prescription, OTC), Dosage Form (Eye Drop, Gel), Distribution Channel, Global Forecast, 2024 - 2032
Ophthalmology Drugs Market is anticipated to record a CAGR of 5.1% from 2024 to 2032, driven by increasing incidences of eye disorders and diseases such as cataracts, glaucoma, and age-related macular degeneration. The World Health Organization report stated that cataracts affected approximately 65.2 million people and caused moderate to severe vision loss in over 80% of cases. This fuels the demand for ophthalmic drugs, as these conditions often require pharmaceutical interventions to manage or treat.
Additionally, ongoing research and innovation in the field lead to the introduction of novel therapies and medications, enhancing the effectiveness of treatments for various eye diseases. These advancements not only address existing medical needs but also offer new and improved solutions, thus attracting both healthcare professionals and patients.
Ophthalmology drugs industry is segmented based on dosage form, therapeutic class, indication, route of administration, product, distribution channel, and region.
Anti-inflammatory drugs segment is poised for substantial growth in the forecast period, as they help in managing various inflammatory eye conditions. Inflammation is a common factor in numerous eye disorders, such as uveitis and dry eye syndrome. Anti-inflammatory drugs, including corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs), effectively address these conditions by reducing inflammation and alleviating symptoms.
Myopia segment will generate notable revenues for the market during 2024-2032, propelled by the escalating prevalence of nearsightedness. The increasing reliance on digital devices and prolonged screen time, especially among younger populations, is leading to surge in myopia cases. As the demand for effective solutions to manage and curb myopia rises, pharmaceutical companies are investing in R&D, leading to the introduction of novel drugs that cater specifically to this need.
Asia Pacific ophthalmology drugs industry is slated to witness a significant growth rate through 2032, attributed to rising healthcare awareness. There is an increasing prevalence of eye disorders, notably among the aging population in the region. Rapid urbanization and lifestyle changes contribute to a surge in eye-related conditions. Furthermore, the accessibility to healthcare services and heightened awareness about the importance of eye health are driving individuals to seek early diagnosis and treatment, thereby boosting the demand for ophthalmology drugs. The advancements in healthcare infrastructure and a growing emphasis on preventive care are stimulating the regional market growth.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market definition
- 1.2 Base estimates & calculations
- 1.3 Forecast parameters
- 1.4 Data validation
- 1.5 Data Sources
- 1.5.1 Primary
- 1.5.2 Secondary
- 1.5.2.1 Paid sources
- 1.5.2.2 Public sources
Chapter 2 Executive Summary
- 2.1 Global ophthalmology drugs industry 360 degree synopsis, 2018 - 2032
- 2.1.1 Business trends
- 2.1.2 Regional trends
- 2.1.3 Therapeutic class trends
- 2.1.4 Indication trends
- 2.1.5 Route of administration trends
- 2.1.6 Product trends
- 2.1.7 Dosage form trends
- 2.1.8 Distribution channel trends
Chapter 3 Ophthalmology Drugs Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing prevalence of eye disorders
- 3.2.1.2 Rising research and development pertaining to the development of novel drugs
- 3.2.1.3 Technological advances in diagnostic and treatment modalities
- 3.2.1.4 Increase in awareness of eye disorders
- 3.2.1.5 Growing geriatric population
- 3.2.1.6 Increasing focus on developing combination therapies
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 Loss of patent protection for popular drugs
- 3.2.2.2 Lack of health insurance in the developing countries
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.3.1 By therapeutic class
- 3.3.2 By indication
- 3.3.3 By route of administration
- 3.3.4 By product
- 3.3.5 By dosage form
- 3.3.6 By distribution channel
- 3.4 Regulatory landscape
- 3.4.1 U.S.
- 3.4.2 Europe
- 3.5 Pipeline analysis
- 3.6 Porter's analysis
- 3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company matrix analysis, 2023
- 4.3 Competitive analysis of major market players
- 4.4 Competitive positioning matrix
- 4.5 Strategy dashboard, 2023
Chapter 5 Ophthalmology Drugs Market Size and Forecast, By Therapeutic Class, 2018-2032 (USD Million)
- 5.1 Key trends, by therapeutic class
- 5.2 Anti-VEGF agents
- 5.3 Anti-glaucoma drugs
- 5.3.1 Alpha agonist
- 5.3.2 Beta blockers
- 5.3.3 Prostaglandin analogs
- 5.3.4 Combined medication
- 5.3.5 Other anti-glaucoma drugs
- 5.4 Anti-inflammatory drugs
- 5.4.1 Steroids
- 5.4.2 NSAIDs
- 5.5 Anti-infective drugs
- 5.5.1 Anti-bacterial drugs
- 5.5.2 Anti-fungal drugs
- 5.5.3 Other anti-infective drugs
- 5.6 Anti-allergy drugs
- 5.7 Other therapeutic categories
Chapter 6 Ophthalmology Drugs Market Size and Forecast, By Indication, 2018-2032 (USD Million)
- 6.1 Key trends, by indication
- 6.2 Dry eye
- 6.3 Glaucoma
- 6.4 Infection/inflammation
- 6.5 Retinal disorders
- 6.5.1 Wet AMD
- 6.5.2 Dry AMD
- 6.5.3 Diabetic retinopathy
- 6.5.4 Other retinal disorders
- 6.6 Allergy
- 6.7 Uveitis
- 6.8 Myopia
- 6.9 Ptosis
- 6.10 FECD
- 6.11 Retinitis pigmentosa
- 6.12 Other indications
Chapter 7 Ophthalmology Drugs Market Size and Forecast, By Route of Administration, 2018-2032 (USD Million)
- 7.1 Key trends, by route of administration
- 7.2 Topical
- 7.3 Local ocular (intravitreal)
- 7.4 Other routes of administration
Chapter 8 Ophthalmology Drugs Market Size and Forecast, By Product, 2018-2032 (USD Million)
- 8.1 Key trends, by product
- 8.2 Prescription
- 8.3 OTC
Chapter 9 Ophthalmology Drugs Market Size and Forecast, By Dosage Form, 2018-2032 (USD Million)
- 9.1 Key trends, by dosage form
- 9.2 Eye drops
- 9.3 Capsules and tablets
- 9.4 Gels
- 9.5 Ointments
- 9.6 Injectables
- 9.7 Cream
- 9.8 Other dosage forms
Chapter 10 Ophthalmology Drugs Market Size and Forecast, By Distribution Channel, 2018-2032 (USD Million)
- 10.1 Key trends, by distribution channel
- 10.2 Hospital pharmacies
- 10.3 Retail pharmacies
- 10.4 Online pharmacies
Chapter 11 Ophthalmology Drugs Market Size and Forecast, By Region, 2018-2032 (USD Million)
- 11.1 Key trends, by region
- 11.2 North America
- 11.2.1 U.S.
- 11.2.2 Canada
- 11.3 Europe
- 11.3.1 Germany
- 11.3.2 UK
- 11.3.3 France
- 11.3.4 Spain
- 11.3.5 Italy
- 11.3.6 Rest of Europe
- 11.4 Asia Pacific
- 11.4.1 Japan
- 11.4.2 China
- 11.4.3 India
- 11.4.4 Australia
- 11.4.5 South Korea
- 11.4.6 Rest of Asia Pacific
- 11.5 Latin America
- 11.5.1 Brazil
- 11.5.2 Mexico
- 11.5.3 Rest of Latin America
- 11.6 Midde East & Africa
- 11.6.1 South Africa
- 11.6.2 Saudi Arabia
- 11.6.3 Rest of Middle East & Africa
Chapter 12 Company Profiles
- 12.1 AbbVie, Inc.
- 12.2 Alcon Vision LLC
- 12.3 Bausch Health Companies, Inc.
- 12.4 Bayer AG
- 12.5 Coherus BioSciences
- 12.6 F. Hoffmann-La Roche Ltd.
- 12.7 Novartis AG
- 12.8 Pfizer, Inc.
- 12.9 Regeneron Pharmaceuticals, Inc.
- 12.10 Santen, Inc.
- 12.11 Sun Pharmaceutical Industries Ltd.
- 12.12 Teva Pharmaceutical Industries Ltd.
